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Abstract 
 
 Carbohydrate transporters or GLUTs of the major facilitator superfamily 
(MFS) are responsible for transporting sugars into the cell and have been of 
research interest for decades. Disruptions, mutations, and over-activations of GLUTs 
have been linked to a number of major diseases including cancer, obesity, and 
diabetes. Differentiating between transporters is incredibly difficult due to highly 
conserved structures, and so specific targeting between transporters has proven a 
complex challenge. GLUTs are highly flexible in their conformations however exactly 
what will and will not pass through the transporter is ambiguous at best, and many 
attempt to target these transporters have failed.  
 In an attempt to further understand GLUT5’s transport capacity and specificity 
several probes were created by conjugating 1-amino-2,5-anhydro-D-mannitol with a 
number of fluorescent coumarins. These probes were then tested in cancer and 
normal breast cell lines to determine uptake mechanisms and transport specificity. 
To determine transport specificity probes were tested in the presence of competitive 
and non-competitive inhibitors. Probe analysis was carried out by evaluating the 
gained fluorescence of treated cells in a microplate setting and through confocal 
microscopy. Confocal imaging and Z-stack was utilized to understand the ability of 
the probe to pass into the cytosol or to remain in the cellular membrane. As a result, 
probes reflecting uptake capacity vs. membrane expression of the transporter were 
developed. The cumulative analysis of structure-uptake relationship for the 
developed probes gives insight into the capability of GLUT5 cargo transport and as 
well as a method for imaging GLUT5 in the cellular membrane.  
xi
Chapter 1 
Introduction 
1.1  GLUTs: classification and expression 
GLUTs (facilitative glucose transporters) are expressed throughout the body and 
are vital for survival of cells. Gluts mediate a gradient dependent transport of 
carbohydrates into and out of the cell but cannot export their substrate’s 
phosphorylated counterparts [1, 2]. There are fourteen known GLUTs and based on 
sequence, structural and substrate similarities are split into three major classes: 
Class I, II and III. Class I GLUTs (1-4 and 14) primarily facilitate uptake of glucose, 
but some are responsible for various other hexoses (Table 1). Class II GLUTs (5, 7, 
9 and 11) are primarily fructose transporters, and Class III GLUTs (6, 8, 10, 12, and 
13 (HMIT1)) are structurally atypical members of the GLUT family.  
GLUT2-4 are relatively localized in specific areas. GLUT2 is mainly located in the 
liver and gastrointestinal tract. GLUT3 is primarily located in neuron cells and mainly 
transports glucose. GLUT4 is the unique of the class I transporters as it mainly 
reside inside the cell and is only brought to the surface in the presence of insulin. In 
low insulin concentrations, it resides in intracellular vesicles inside the cell membrane 
and is predominately present in skeletal and cardiac muscles [25]. GLUT4 has been 
found to have links with insulin resistance and diabetes and has been a potential 
therapeutic target [26]. 
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 Table 1. Glut Transporters 
Class Transporter Expression in Normal Cells Substrate 
Class I 
Glut1 erythrocytes glucose, galactose 
Glut2 
renal tubular, intestinal 
epithelial, liver and 
pancreatic β cells 
glucose, 
galactose, 
fructose, 
glucosamine 
Glut3 neurons and placenta 
glucose, 
galactose, 
mannose 
Glut4 adipose tissue and striated muscle 
glucose, 
galactose, 
mannose, xylose 
Glut14 testis glucose, galactose 
Class II 
Glut5 intestinal epithelial, erythrocytes, sperm fructose 
Glut7 apical membrane in small and large intestine glucose, fructose 
Glut9 liver, kidney and intestine glucose, fructose 
Glut11 muscle, heart, fat, placenta, kidney, and pancreas glucose, fructose 
Class III 
Glut 6 
renal tubular, intestinal 
epithelial, liver and 
pancreatic β cells 
glucose 
Glut 8 testis, brain, fat, liver, and spleen glucose, fructose 
Glut 10 heart and lung glucose, galactose 
Glut 12 insulin-sensitive tissues 
glucose, 
galactose, 
fructose 
Glut 13 Brain myoinositol 
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1.2  GLUTs: Structure and Mechanism of Function 
GLUT structures are highly conserved and are typically two bundles of six 
transmembrane helixes (TM) with four to five intercellular helixes (IC) for stabilization 
[16, 17]. GLUTs rely on a concentration gradient to transport substrates; it is based on 
substrates moving from an area of high concentration (typically outside the cell) into 
an area of low concentration (typically inside the cell). Transportation begins with 
outward-open conformation of GLUTs, and a substrate binds substrate active site. 
Once key residues have been bound, interactions between TMs trigger a 
conformational change within the transporter that orients the substrate to the 
endofacial binding site. Once deposited into the cell, the substrate can be effectively 
excreted via the same pathway. However, in the conditions of sufficient carbohydrate 
phosphorylation, carbohydrate excretion is believed to play an insignificant role in 
evaluating the kinetics of the uptake [18-20], because GLUT transporters being 
antiporter take up and excrete carbohydrates, but not their phosphorylated analogs 
[21]. As a result, sugar transport is loosely coupled to phosphorylation, so that a high 
rate of sugar accumulation is maintained without requiring a reduction in the 
intracellular sugar concentration.  
1.2.1 Class I: GLUTs 1-4 
GLUT1 is the most widely studied and targeted of the GLUT transporters and is 
currently the key target in Positron Emission Topography (PET) imaging using a F18-
labelled glucose and is widely used throughout the world as a potent cancer imaging 
agent. GLUT1 has twelve transmembrane (TM) segments split into two six-helix 
bundles carboxy- and amino- domains (C and N respectfully). The transporter 
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preferentially sits in an exofacial conformation stabilized by inter-TM salt bridges on 
the endofacial side of the transporter that are not present in the endofacial-open 
conformation of the transporter. When glucose enters the binding site increased 
interactions between C and N domains and with a protonation of Asp126 leads to 
cation-π interaction with the aromatic Tyr292 residue causes the transporter to adopt 
the intercellular conformation. With the release of the substrate via concentration 
gradient interactions between C and N residues equilibrate and with a deprotonation 
returns to the original extracellular state [16].  
Central cavity of GLUT1 encompasses a multitude of residues including 
Phe26, Gln166, Ile169, Ile173, Gln287, Gln288, Asn324, Phe379, Gly384, Trp388, 
Asn411, and Trp419, with most of these residues residing on the C-terminal of the 
protein leading to asymmetrical binding site [17]. Understanding what is necessary for 
binding and what can be tolerated to initiate transport is vital for designing anything 
from probes to cytotoxic therapies for GLUT1. To determine the vital interactions, a 
large series of structural activity relationship (SAR) studies have been conducted. 
Early studies have shown that GLUT1 has a highly effective in transporting D-glucose 
while struggles to transport L-glucose, suggesting the transport to be sensitive towards 
stereochemistry of the glucose hydroxyls [22]. In agreement with these observations, 
glucose anomers have shown a loss in the uptake efficiency. Poor uptake was also 
documented for glucose analogs bearing alkoxy groups. Contrary to effects observed 
by removal of the C2 and C9 hydroxyls which did not impact the uptake of glucose, 
with resulting 2-deoxy and 6-deoxy-D-glucose competing for uptake with D-glucose 
[23]. Building upon these findings 2-chloro and 2,2’-dichlor-2-deoxy-D-glucose were 
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found to have similar binding affinity to D-glucose, suggesting C2 position may serve 
as an accommodating position for payload conjugation.  
Table 2. Structure-Uptake relationship of GLUT uptake 
Substrate 
Transport Rate, (%) 
Glut1a Glut2b Glut3b Glut4b 
Controls     
D-glucose 1 20±6 10±2 12±3 
L-glucose 95 100 100 100 
     
C1 Analogs     
1-Deoxy-D-glucose 82 109±10 104±12 79±12 
     
C2 Analogs     
2-Deoxy-D-glucose 1 20±2 12±2 14±9 
D-Mannose 33 29±3 14±2 13±7 
2-Chloro-D-glucose n.d. 76±5 42±3 40±7 
     
C3 Analogs     
3-O-Methyl-D-glucose 30 73±6 17±3 41±7 
3-O-Propyl-D-glucose n.d. 100±12 80±7 72±8 
3-Deoxy-D-glucose 67 103±12 85±7 106±12 
3-Bromo-D-glucose n.d. 95±10 75±4 79±12 
3-Fluoro-D-glucose  85±5 14±2 40±6 
D-Allose 75 59±6 96±7 96±7 
     
C4 Analogs     
D-Galactose 48 110±12 57±5 96±12 
     
C5/C6 Analogs     
6-Deoxy-D-glucose 8 33±9 46±7 44±7 
D-Xylose n.d. 106±9 78±6 75±6 
L-Arabinose n.d. 138±22 63±7 90±8 
6-O-Methyl-D-galactose 95 57±10 109±11 59±6 
6-Fluoro-D-galactose n.d. 50±12 30±9 48±12 
Transport rate determined relative to the uptake of aD-[3H]-glucose; b[2,6-3H]-2-deoxyglucose;n.d., 
not determined. 
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Continues testing has revealed that glucose recognition is highly dependent on 
the C1-OH as an H-bonding acceptor and the binding has been suggested to work in 
tandem with hydrophobic interactions on the C6 position. C1 methylation, removal or 
substitution (with exception of 1-fluoro-D-glucose) all demonstrated exceptional loss 
of uptake [9, 23, 24]. Although removing C6 hydroxyl still permitted glucose transport, 
any significant bulk on the position reduced transporter affinity.  Overall SAR studies 
have identified C1, C3 and C4 hydroxyls and C6 hydrophobic interactions are critical 
points for glucose binding to the active site in GLUT1. 
GLUT2, 3 and 4 share many key H-bonding interactions when transporting 
glucose as GLUT2 and 3 require the presence of C1, C3 and C4 hydroxyls for effective 
glucose transport [11]. Like with GLUT1 C2 substitution was tolerated but did 
negatively impact uptake with GLUT2 being the most sensitive to this alteration. 
GLUTs 2-4, unlike GLUT1, are not glucose specific and have been found to transport 
D-mannose as efficiently as D-glucose. GLUT1 and 3 can effectively transport 3-
fluoro-D-glucose but GLUT2 being unable, pointing towards a C3-OH H-donating 
effect not required in GLUT3 or 4 [10]. Both GLUT2 and 4 can transport O-6-methyl-
D-galactose, but GLUT3 shows little to no affinity. All three can transport the 6-fluoro 
analog hinting towards extended hydrophobic interactions required in GLUT2 and 
GLUT4 while GLUT3 has a low tolerance for any steric interactions. Although no 
crystal structures of GLUT2-4 it is likely that they share similar structures however it is 
difficult to know if they have more or less TM or ICH.   
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1.2.2 GLUT5 
Class II transporter GLUT5 is the only known transporter that specifically transports 
fructose and nothing else. In conjunction with GLUT2, they are responsible for most of 
the fructose transport in the human body [27]. GLUT5 has been a topic of increasing 
interest in recent years as it has been found to be overly active in breast cancer, while 
at relatively inactive levels in normal breast cells [28]. Unlike most GLUTs, GLUT5 has 
had a crystal structure released (Figure 2) and has shown large conservation between 
GLUT1 but with some key differences. Like GLUT1 it is two bundles of six 
transmembrane helixes however it has five intercellular helixes that are key for 
stabilization. Inter-TM salt bridges are a common stabilizing force in major facilitator 
superfamily transporters and are present only while GLUT5 is in the outward-facing 
conformation. The observed salt bridges are formed between C-terminal helixes TM3, 
4 and 5 and form between N-terminal helixes TM9, 10 and 11. Glu151 (TM4) forms 
two salt bridges between two arginine residues: Arg97 (TM3) and Arg407 (TM11) 
whereas Glu400 (TM10) also binds to Arg158 (TM5) and Arg340 (TM9) to complete a 
stable network between the two terminals.  
When GLUT5 transitions to the inward-open conformation, no C-N terminal salt 
bridges are observed, and the conformational change in the transporter facilitates the 
entering and exiting of the substrate. Further indicating a preference to outward-open 
is the linking of Glu252 (ICH3) forming salt bridges with Arg407 (TM11), which is 
broken upon the inward-open conformation. The most important transitions that take 
place in GLUT5 occur in TM7 and TM10 as both undergo dramatic shifts to facilitate a 
conformational change. TM7 shifts down towards the binding site as substrate enters 
the central cavity whereas TM10 moves away from the binding site breaking the strong 
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interactions of Tyr382 (TM10) and Ile295 and Val292 (TM7) and allowing fructose 
transport. These observations suggest TM7-TM10 interactions play an integral role in 
transport kinetics [17]. 
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 = 15.0 mM           
allyl, Ki = 28.5 mM
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4
6
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Figure 1.1: Comparison of interaction of C2-derivatives of furanose and pyranose ring forms of fructose 
with GLUT5. Inhibitory constants were derived by monitoring inhibitory effect of analogs on the uptake 
of [14C]-D-fructose into CHO cells expressing Glut5. 
The binding site for fructose has been extensively studied by Holman et al. [13, 
29-31], and determined that stereochemistry and presence of hydroxyls be vital to 
substrate uptake (Figure 1.1). GLUT5 mediated fructose uptake was found to prefer 
beta-anomers over alpha-anomers determined by testing C2-methylated 
fructopyranose and fructofuranose analogs [13]. Alterations of stereochemistry of ring 
hydroxyls or alkylation was found to dramatically limit affinity to GLUT5 with the notable 
exception of the C2 position. When 2,5-anhydro-D-mannitol was tested it revealed that 
the anomeric hydroxyl plays little to no role in GLUT5 fructose transport and that 
GLUT5 effectively takes up fructose in its furanose form as opposed to its pyranose 
form [29]. Cyclic oxygen has been found to be vital for uptake via GLUT5 as thio-
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substitution led to six-fold loss of uptake was observed [32]. C2 and C5 stereocenters 
were found to increase uptake during an anti-relationship when comparing 2,5-
anhydro-D-mannitol uptake vs. L-sorbose (Figure 1.2).  
OHO OH
OH
HO OH
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α = 1%, β = 4%
O
OH
OH
OH
OH
HO
D-tagalopyranose
α = 79%, β = 16%
81%
4%
OHO OH
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O
OH
OH
OH
OH
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46%
54%
Ki = 59 mM
Ki = 134 mM
OHO OH
OH
HO OH
L-sorbose
Ki
 = 143 mM
SHO OH
OH
HO OH
5-thio-D-fructose
Ki
 = 96 mM  
Figure 1.2: Conformer ratios and inhibitory constants for fructose uptake via GLUT5 for D-fructose, D-
psicose, and D-tagatose. 
The Holman team envisioned a locked series of analogs may provide key 
insight in GLUT5 binding and potentially series of GLUT5 specific probes (Figure 1.3). 
These probes were split into type I and type II and differed in existence of the C1 
hydroxyl with type I maintaining while type II removed. Type I scaffolds were tested to 
inhibit D-fructose uptake in the presence of both C1 hydroxyl and ether and was found 
to inhibit uptake in both cases [31]. In the presence of a carbonyl, oxazolidine uptake 
was nearly 4-fold higher than its thio counterpart pointing towards key oxygen 
interaction with the transporter. Type II analogs failed to inhibit D-fructose uptake 
regardless of stereochemistry, indicating that C1 and C6 oxygens are vital for transport 
in GLUT5, but C1 acts primarily as an H-bond acceptor or a similar coordination with 
the transporter. These studies in conjunction with crystal structure have given a good 
image on what GLUT5 will tolerate to induce binding, but severe limitations persist in 
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understanding size and functionalization of payloads that transporter permits to pass 
through.  
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Figure 1.3: Bicyclic furanose analogs testing GLUT5 uptake conditions 
1.3  GLUTS in Therapy  
As discussed previously, PET imaging is one of the most successful utilization 
of overactive GLUT transport in diseased cells (mainly cancer), but it is not the only 
one currently in use and development. Quantifying transporters in the membrane has 
several limitations and involve time-consuming experiments such as western blots or 
extensive mutagenesis. Monitoring carbohydrate mimics uptake gives a quick and 
telling analysis of relative expression and activity of transporters that are being 
specifically targeted.  
1.3.1 Carbohydrates as diagnostic probes 
The apparent relationship between deregulated carbohydrate 
uptake/metabolism and disease has triggered interest in GLUT-targeting diagnostic 
probes. SAR and kinetic analysis of various substrates (described above) have led to 
the development of radiolabeled probes as well as fluorescent analytical probes. The 
understanding that C2 and C6 hydroxyls do not play a role in the uptake provided 
handles for halogenated analogs to act as radiotracers to measure glucose uptake in 
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diseases. 2-Deoxy-D-glucose (FGD) was first reported by Pacak and co-workers in 
1968 [33], and the first 18F-labeled analog (18F-FGD, 1, Figure 6) was reported by 
Brookhaven National Laboratory in 1978 [34]. 18F-FDG is rapidly transported into a 
cancerous cell due to its increased metabolism and undergoes phosphorylation to 
prevent excretion. Increased intracellular accumulation of 18F-FDG in cancerous cells 
provides key insight into important cancer characteristics namely enhanced glucose 
transport as well as enhanced phosphorylation. 18F-FDG has seen wide use as a 
predictor of tumorigenesis [35-39]. However, it is ineffective with a large number of 
cancers (including breast cancers) that have reduced glucose uptake capacity [2, 40], 
and produces false-positive hits due to accumulation at the of inflammation [41, 42]. 
Due to limitations of FDG needing to be phosphorylated to remain in the cell to 
accurately measure glucose transport independent of cellular phosphorylation. [123I]-
6-deoxy-6-iodo-D-glucose (6DIG, 2, Figure 1.4) was first synthesized by Wassenaar 
to act as a tracer unaffected by phosphorylation [43]. Biological studies of 6DIG 
performed by Henry and co-workers [44] confirmed that 6DIG underwent cellular 
transport via GLUTs without phosphorylation making it a valuable tool in tracing 
glucose transport. In vitro studies involving adipocytes of diabetic rats and obese mice 
indicated 6DIG as a potential tool for determining glucose transport derivations in 
diseases [45]. 6DIG was found to undergo preferential uptake in adiposities, and 
cardiac cells, both with have high concentrations of insulin-regulated GLUT4 and was 
proposed as a potential in vivo tool to measure insulin resistance. Using diabetic mice 
and insulin-resistant fructose-fed rats, Perret, and coworkers [46-48] determined 
glucose transport defects in vivo using 6DIG.  
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Class II fructose specific transporter GLUT5 has gained considerable attention 
as a potential cancer target due to its alleged role in cancer development [7]. Designed 
by Maeda and co-workers [49], 1-[18F]-Fluoro-1-deoxy-D-fructose (3, Figure 1.4) acted 
as a tracer in to specifically target GLUT5. Synthesized in two steps from 2,3,4,5-di-
O-iso-propilidene-1-O-(trifluoromethane sulfonyl)-D-fructose, 1-[18F]-Fluoro-1-deoxy-
D-fructose rapidly passed through kidney and liver when tested in rat and mouse tumor 
grafts. Development of 6-fluoro-6-deoxy-D-fructose (4, Figure 1.4) [38, 50], found a 
tracer capable of entering murine EMT-6 and the human breast cancer MCF cells. 6-
[18F]-FDF acted as hexokinase substrates and was rapidly metabolised in vivo.  
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Figure 1.4: Glucose and fructose-based PET imaging probes 
The next generation of radiotracer probes was derived from 2,5-anhydro-D-
mannitol based on its high affinity towards GLUT5. Niu tested PET imaging agent [39]  
1-[18F-fluoro]-1-deoxy-2,5-anhydro-D-mannitol [51] (5, Figure 1.4) in breast cancer 
solid tumours. Results displayed rapid excretion after internalization by cancerous 
cells requiring optimization to increase retention. 3-(18F)fluoro-3-deoxy-D-fructose (6, 
Figure 1.4) developed by Cheeseman et al. [52] showed fructose specific transport by 
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a series of competitive uptake inhibition studies and was shown to enter multiple 
cancer cells lines including EMT-6, CHO, and MCF. Although not as successful as 
glucose PET imaging tracer, preliminary results have warranted development of more 
stable and easily retained fructose analogs for PET imaging in the future.  
1.3.2 Carbohydrates in chemotherapy 
Glycoconjugation provides a potentially elegant way of preferentially targeting 
cancerous cells in the presence of normal, healthy cells by targeting the overactive 
metabolism of cancer [14]. Glufosfamide (8, Figure 1.5) acted as a prodrug, remaining 
inactive until cleavage of the glucose after endocytosis into the cell and was one of the 
first glycoconjugated drugs used [14]. Glufosfamide failed to pass phase II clinical trials 
for unknown reasons, however, did specifically target glucose transport and provided 
a potential starting point. Glycoconjugation has been used in an attempt to increase 
specificity for existing drugs such as chlorambucil which was conjugated to several 
sugars in an attempt to improve specificity and cytotoxicity [53]. Chlorambucil was 
conjugated with 63 compounds including glucose (7, Figure 1.5), mannose, galactose, 
and xylose, and conjugation were shown to improve cytotoxicity up to 8-fold [54]. It is 
unknown if chlorambucil’s increased cytotoxicity was caused due to a GLUT-transport 
or increased accumulation in the cell due to sugar conjugation but it is a likely 
hypothesis. Conjugates were not limited to chlorambucil and have been developed for 
the following (not limited to) anticancer agents: azinomycin, clioquinol, adriamycin, 
warfarin, cyclopamine, 8-[O6-(4-bromothenyl)-guanine, quinolinyl and methane 
sulfonate, and paclitaxel (Taxol), with varying success [14].  
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Lactate dehydrogenase (LDH) inhibitors [55] were developed with the intention 
of selectively target tumors and act as a photosensitizer [56]. LDH inhibitor N-hydroxy 
indole (NHI) (9, Figure 1.5) [55] conjugated of glucose or mannose lead to a noticeable 
increase (4.5-fold) in antiproliferative effect as well as a similar increase in inhibiting 
LDH. Likewise, glucose conjugates of 5,10,15,20-tetrakis-2,3,5,6-tetrafluorophenyl-
2,3-(methanol(N-methyl) iminomethano) chlorin (10, Figure 1.5) were developed with 
the intention of being a selective and more potent cytotoxic drug (H2TFC-S-Glc). 
H2TFC-S-Glc did show more potency than other photosensitizers but remained non-
specific, this is likely due to the substitution of the anomeric hydroxyl (shown previously 
to be vital for binding) and points to non-GLUT mediated uptake behind the loss of 
specificity.  
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Figure 1.5. Carbohydrates as cancer-directing encore in drug delivery 
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Platinum (Pt) and palladium (Pd) complexes have seen incredible success in 
cytotoxicity, but due to lack of specificity lead to horrific side effects, glycoconjugation 
was attempted to increase specificity in a number of complexes. Tanaka et al. [57] 
have tested C2-Pt and C2-Pd glucose conjugates in vivo on gastric cancer cells that 
have been shown to be cisplatin-sensitive and cisplatin-resistant. Like typical cisplatin, 
apoptosis was induced by coordination between grooves of the DNA and preventing 
DNA replication. However, both compounds were found to be less effective and no 
more specific than typical cisplatin. It is unknown whether the compounds were 
transported via GLUTs or through some other process and the glucose may have 
caused steric issues with coordination in DNA to decrease activity.  
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Figure 1.6. Glucose as a delivery platform for platinum compounds. 
Lippard, and coworkers [58] were able to identify GLUT preference of C1 and 
C2 conjugation of Pt and Pd derivatives after screening several isomers. These results 
agree with previous observations studies [9, 24]. In a separate studies, Lippard and 
coworkers have designed and evaluated C6-Pt conjugates (11-14,  Figure 1.6) that 
differed in the linker length between Pt and the carbohydrate.[59] Using bacterial 
xylose transporter XylE, which is very similar to GLUT1, molecular docking studies 
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showed conjugates undergoing H-bonding interactions with key residues Gln288, 
Gln168, Gln175 and Tyr298 pointing towards GLUT-mediated uptake.  
4,6-O-ethylidene-α-D-glucose (EDT) in the presence of conjugates 11-14 was 
found to inhibit uptake indicating GLUT1 as the route for intercellular uptake and was 
found to decrease as linker length was increased [60]. Aglycone 13 was found not 
undergo GLUT-mediated uptake and likely go through passive diffusion [59]. Pt-
glucose conjugates were found to have similar cytotoxicity of aglycone 13 and higher 
than cisplatin in a number of human cancer cells. Cytotoxicity was experienced after 
shorter incubation periods indicating the difference in kinetics between facilitative 
GLUT transport vs. that of passive diffusion that aglycone and cisplatin rely on. The 
compounds 11 and 12 were found to platinate DNA leading to cell apoptosis, with the 
number of platinated residues relatively similar to oxaliplatin. The uptake of 11-14 was 
also found to different extend to depend on the organic transporter 2 (OCT2, involved 
in the uptake of 14), with 11 showing more GLUT-specific uptake that other analogs. 
Further evaluation showed 11 to be more cytotoxic in cancer vs. normal cells, giving a 
good platform for further development of cancer-specific therapeutic agents.  
Glycoconjugation has also been used in an attempt to increase selectivity for 
a variety of other nonspecific methods of drug delivery. Nanoparticles have been 
widely studied as potent delivery systems for highly cytotoxic payloads but suffer from 
lack of specificity [61]. In an attempt to increase specificity glycoconjugation with 
nanoparticles has been attempted with varying success [62]. Li and co-workers [62] 
developed glucose-conjugated chitosan nanoparticles in an attempt to encapsulate 
doxorubicin with limited success. Doxorubicin-loaded nanoparticles entered 4T1 
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cancer cells up via GLUTs and were four times more cytotoxic than non-glucose-
conjugated nanoparticles [63]. 
Glycoconjugation has not been limited to just cancer and has found success in 
delivering payloads through the blood brain barrier due to high amounts of GLUT1 [64, 
65] as well as other barrier structures in the brain [66]. A successful example was 
ibuprofen-glucose conjugation resulting a dramatic increase in drug delivery to the 
brain with a three-fold increase in concentration [15]. The massive challenges BBB 
penetration and water solubility represent for most small molecule drugs prodrug 
development with glucose provides an elegant solution to both of these issues and 
represents potentially effective drug delivery system for future drugs [67]. 
1.3.3 Fluorescent GLUT Probes 
Targeting GLUTs has been attempted a variety of fluorescent conjugates. 
However, the only fluorophore found to pass through GLUTs was green-fluorescent 7-
nitrobenzofurazan (NBD). Conjugation of amino sugars – 2-Amino-2-deoxy-D-glucose 
(G) [68], 1-deoxy-1-amino-D-fructose (F) [69], and 1-amino-2,5-anhydro-D-mannitol 
(M) [70]  with NBD has produced a probes specific for certain GLUTs (Figure 1.7).  
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Figure 1.7: Green fluorescent GLUT-targeting probes 
NBDG is glucose dependent [68, 71], and is likely passes through most class 
I transporters. NBDF uptake is facilitated by glucose- and fructose-transport and is 
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likely to rely on GLUT2 and GLUT5 [69].  MNBD uptake depends only on fructose and 
likely passes specifically through GLUT5, suggesting some preference of the 
transporter towards the locked furanose ring. Altogether, NBDG, NBDF, and NBDM 
allow assessing the efficiency of glucose-specific transport, non-specific transport and 
fructose-specific transport, respectively, providing convenient tools for quick analysis 
of carbohydrate transport efficiency in various cells. All three probes were found to be 
phosphorylated inside the cell, ensuring their cellular accumulation and retention [72]. 
Limited attempts to produce red fluorescent probes by conjugating carbohydrate to 
cianine5 (Cy5) dye resulted in a loss of GLUT-mediate uptake [69], leaving room for 
further evaluation of transporter preferences in substrate selection. Fluorescent 
probes have wide room for improvement as NBD competes with auto-fluorescence of 
cells in the green region and various colors provide an opportunity of tracking various 
transporters activity simultaneously.  
This thesis work focuses on our attempts to develop fructose uptake 
dependent fluorescent probes. Synthesis and probe design will be discussed in 
Chapter 2 while cellular studies will be discussed in Chapter 3. Future research plans 
for additional probes and cancer types will be summarized in Chapter 4. 
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 The following material is in preparation for submission to a journal for publication.  
 
Chapter 2 
Blue Fluorescent Probes GLUT-Mediated Uptake in Breast Cancer 
 
2.1 Introduction 
Carbohydrate uptake in mammalian cells is facilitated by membrane proteins 
called GLUTs which perform gradient-dependent carbohydrate transport [1, 2]. 
Expression of GLUTs varies throughout the body and can be viewed as a physiological 
characteristic of the tissue. Mutations of GLUTs have been linked with several medical 
conditions [3] while alterations to GLUT activity and regulation are characteristic for 
the metabolically-compromised cell, including cancer cells [4]. GLUT research has 
been mainly focused on widespread glucose transporter GLUT1 due to its high activity 
in various cancers. Recent findings have increased interest in the fructose-specific 
GLUT5 that appears to be expressed in various cancers, while absent in the 
corresponding non-cancer tissues [5].  
 The kinetic analysis of carbohydrate transport via GLUTs led to the 
development of the transport model that included the binding of the substrate to the 
extracellular site of the transporter, followed by the conformational change in the 
enzyme and the translocation of the substrate to the intracellular or endofacial side of 
the membrane [6]. Initial binding of the substrate to the transporters was found to vary 
with the structure of a carbohydrate, i.e. to depend on sugar conformation and the 
presence and stereochemistry of hydroxyls [7-11]. The understanding molecular basis 
for sugar-transporter interaction facilitated the development of biochemical probes to 
analyze transport efficiency, and dissect the membrane portion from the total GLUT 
expression. The latter provides the possibility for cell differentiation based on profiling 
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the membrane GLUTs. GLUT-targeting imaging agents and drugs conjugates are of 
interest to distinguish and kill metabolically-compromised cells [12], or to penetrate the 
blood-brain barrier [13]. Therapeutic approaches also include inducing a nutrient 
deficit in cancers, thus stimulating the development of carbohydrate uptake 
modulators.  
Current knowledge of GLUT-substrate interactions and the transport capacity 
of GLUTs is currently limited and requires significant study to determine. Conjugation 
of amino sugars – 2-Amino-2-deoxy-D-glucose [14], 1-deoxy-1-amino-D-fructose [15], 
and 1-amino-2,5-anhydro-D-mannitol [16] to the fluorescent 7-nitro-2,1,3-
benzoxadiazole (NBD) has led to effective GLUT uptake probes. However, the efforts 
to produce fluorescent conjugates of other colors (Cy5-fluorophore) failed, and GLUT-
Cy5 conjugate showed to lose GLUT-mediated uptake [15]. Coumarins are aromatic, 
blue fluorescent molecules with a similar size to NBD with an easily substituted C4 
position to make a multitude of probes. GLUT2 and GLUT5 have been shown to be 
the two primary transporters responsible for fructose transport but whether they both 
transport fructose in its pyranose or furanose form remains unclear [17]. In this chapter 
the synthesis of ManCou1, 2 and 3 as well as their effectiveness as imaging probes in 
various cancerous and normal cell lines.  
2.2 Materials and Methods 
Materials and methods: Ethanol (ACS/USP Grade, 190 Proof) was purchased from 
Pharmaco-Aaper, USA. Sterile DMSO (25-950-CQC, 250mL) was from Cellgro, USA. 
RPMI-1640, DMEM/, Penicillin/Streptomycin, FBS (Fetal Bovine Serum), Sodium 
Pyruvate (100 mM), 0/25% Trypsin-EDTA (1X), Hank’s buffer, PBS (phosphate 
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buffered saline solution), and RPMI-1640 were was from Life Technologies, USA. 
Cholera Toxin, Vibrio cholerae, Type Inaba 569B, Azide Free was from Calbiochem, 
EMD Millipore, USA. Life Technologies, USA. PBS 1X solution was from Janssen 
Pharmaceutica, Belgium. LIVE/DEAD® Viability/Cytotoxicity Kit, for mammalian cells 
was from Invitrogen, USA. 
Chemical reagents used for the synthesis were purchased from Aldrich. 
Column chromatography was performed using SiliCycle silica gel (230-400 mesh). 
Purification of NBD conjugates for cell studies was performed on Agilent HPLC 1200 
Series equipped with fraction collector from Agilent Technologies, using Phenomenex 
C18 column (Luna 5u C18(2) 100A, 250x4.60 mm, 5 micron) using MeOH:H2O as a 
mobile phase. Structural analysis of compounds was carried out with 400 MHz Varian 
NMR instrument. Spectra are reported in parts per million (ppm) relative to the solvent 
resonances (δ), with coupling constants (J) in Hertz (Hz). UV-vis spectra were 
recorded on a Cary 100 Bio spectrophotometer from Agilent Technologies. High-
resolution molecular mass was obtained with Orbitrap Elite mass spectrometer. UV 
spectra were obtained with Cary-Bio-100 UV-vis spectrometer. Fluorescence spectra 
were obtained with a FluoroMax-4 spectrophotometer. 96-well plate analysis of cell 
fluorescence was carried out with Victor3 fluorescence plate reader (excitation at 385 
nm). Confocal images were taken with Olympus FluoViewTM FV1000 using the 
FluoView software.  
Chemical synthesis of ManCou probes: (2S,3S,4S,5R)-3,4-dihydroxy-5-
(hydroxymethyl)tetrahydrofuran-2-carbaldehyde (1) (1 mmol) and the corresponding 
C4-substituted 7-aminocoumarin (1 mmol) were dissolved in 10 ml of methanol. 0.5 M 
30
 
 
HCl was used to adjust the pH to 5.8 followed by addition of NaCH3CN (1.2 mmol) to 
the reaction mixture. The solution was stirred at room temperature while the pH was 
maintained at 5.8 by periodic addition of 0.5 M HCl until the starting material was no 
longer detectable by TLC.  The mixture was then concentrated to a small volume under 
reduced pressure, and the concentrated residue was separated by the semi-
preparative HPLC (Kinet 2.6 u HILIC 100A) using a various proportion of water-MeCN 
as an eluent. The composition of the final product was confirmed ESI, HRMS, 1H NMR 
and 13C NMR.[18]  
Cell Culture: MCF-7 and MCF-10A cells were seeded from frozen standards 
purchased from ATCC in 10 cm dishes under standard conditions (37 Co, 5% CO2 / 
90% air). MCF-7 cells grown in RPMI-1640 growth medium supplemented with 10% 
heat-inactivated fetal bovine serum (FBS) and 1% penicillin/streptomycin both 
purchased from Thermo-Fisher. MCF10A was grown in DMEM growth media 
supplemented with 10% heat-inactivated fetal bovine serum (FBS), 1% 
penicillin/streptomycin, and cholera toxin (100 ng/ml). MCF7 was passaged with 
trypsin every five days, MCF-10A every ten days with media being changed 24 hours 
after seeding.  
Preparing ManCou solutions: ManCou1 and 2 were dissolved in a solution of 10% 
DMSO/90% Millipore water for stock solution. ManCou3 was dissolved in 70% 
DMSO/30% Millipore water for stock solution. All solutions for testing were diluted from 
stock using Hank’s buffer solution purchased from Thermo Fisher.  
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96-well plate fluorescence studies: At >85% confluence cells were collected and 
plated in 96-well flat bottom plates (20,000 cells/well) purchased from and allowed to 
grow for 24 hours. Cells were then washed with warmed (37 Co) Hank’s balanced 
buffer solution and treated with ManCou fluorescent probes (concentration varies) in 
Hank’s and incubated at 37 Co and 5% CO2 for 10 min. After incubation, the probe-
containing solution was removed, and cells were washed with warmed Hank’s (3 x 100 
µL) buffer. Fluorescent data was immediately collected using Victor3 plate reader and 
using WallacTM umbelliferone (excitation 355 nm, emission 460 nm, 1.0 s) protocol. All 
tests were done in duplicate on each plate.  
Inhibition studies: Using 96-well plate method fluorescence of ManCou probes in 
cells war measure in the presence of varying concentrations of glucose, fructose, 
glucosamine, MNBD, GNBD, and cytochalasin B. Separately, complete culture media 
was used to establish the impact of nutrients on ManCou uptake. Cell incubation, 
washing, and data collection was conducted as stated above. 
Confocal fluorescence studies: At >85% confluence cells were collected and plated 
(20,000) in 35 mm glass-bottom confocal dishes (MatTek) and allowed to grow in their 
respective growth media for 24 hours. Cells were then washed with warmed (37 C°) 
Hank’s (2 x 1 mL) before being incubated with ManCou solution in Hanks (1 mL, 37 
C°, 5% CO2) for 10 min. After incubation cells were again washed with warmed Hank’s 
(3 x 1 mL) and leaving 1 mL of Hank’s for images. Images were taken using Olympus 
FluoViewTM FV1000 using the FluoView software. 60X oil suspended lens cells were 
used to observe fluorescent activity with the following conditions; filter: DAPI, laser: 
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405 (45% intensity), excitation: 10 µs/pixel. Z-stacking was done using FluoView 
software and depth command.  
Fructose preconditioning: MCF7 cells, grown in the standard growth medium, were 
passaged and maintained for ten days in i) the standard medium supplemented with 
fructose (11 mm) to produce fructose-fed MCF7’ cell culture, and ii) in RPMI-1640 
medium supplemented with dialyzed FBS (10%) to produce fructose-deprived MCF” 
cells culture. The MCF” cells were then maintained for ten days in the standard 
medium to produce fructose-refed MCF7* culture. The medium was changed 24 h 
after passaging of cells and every two days. 
2.3 Synthesis and Computational Analysis of Mannitolamin-Coumarin 
Conjugates (ManCou Probes) 
Several coumarins differing in the functional groups at the C4 position (Figure 
2.1) were chosen to assess the possibility to transport extended aromatic system 
through GLUTs and test the impact of steric, H-bonding and electronic interactions. 
ManCou1 (H) represents a plain aromatic system with weakly H-bonding carbonyl 
group that is not expected to exhibit any interactions with the transporter. ManCou2 
(CH3) acts as a weak electron donating group that appears to increase electron density 
of coumarin aromatic system and possibly contributes to the enhanced H-bonding 
capability of the carbonyl group.  ManCou3 (CF3) acts as a strong electron withdrawing 
group deactivating the aromatic system of coumarin and thus increasing its potential 
capability of π-acceptor. Additionally, the presence of halogens is known to induce 
halogen-π interactions within proteins, and CF3 group, in particular, is capable of 
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stabilizing interactions with aromatic systems [19, 20]. Thus, H-bonding and aromatic 
interactions would be expected for ManCou3 within the transporter.  
ManCou1: R = H
ManCou2: R = CH3
ManCou3: R = CF3
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OHHO
HO
O
O
H
N
R
ManCou1 ManCou2 ManCou3
 
Figure 2.1. ManCou1-3 probes and their electrostatic properties 
The synthesis of conjugates was based on the reductive amination of 
(2S,3S,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl) tetrahydrofuran-2-carbaldehyde (1) 
with the corresponding 7-aminocoumarin, resulting in ManCou 1-3 conjugates 
(Scheme 1). To access aldehyde 1, D-(+)-glucosamine was carried through a 
Tiffeneau-Demjanov rearrangement with an acidic resin in the presence of NaNO2 [21]. 
The aldehyde 1 was isolated in acceptable yield (84%) and was used in the 
subsequent reactions without purification. The ManCou conjugates were purified by 
high-pressure liquid chromatography (HPLC) using a gradient of ACN:water and 
analytical (4.5 Å) C18 reverse phase column (Phenomenex). Structures of ManCou1-
3 probes were confirmed with NMR spectroscopy and Mass Spectrometry.  
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Scheme 2.1. Synthesis of ManCou probes 
Optical properties of ManCou1-3 were analyzed through UV-vis (Cary-Bio-100) 
and fluorescence (FluoroMax-4). The UV and fluorescence (Figure 2.2) spectra for 
ManCous 1-3 reflected the impact of a methyl- and trifluoromethyl- substituents on the 
π-system of the fluorophore, with blue- and red-shift observed for ManCou2 and 
ManCou3, respectively. The relative quantum efficiencies of ManCous 1:2:3 were 
established as 0.9:1.0:0.30 (determined for 385 nm excitation wavelength). The 
absolute quantum yields were determined based on the optically matching solution of 
anthracene [22] (20 μM in ethanol, ϕ = 0.27) as 0.26, 0.30, and 0.10 for ManCou1, 
ManCou2 and Mancou3 (20 μM in DMSO/H2O 9:1, v/v), respectively. 
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Figure 2.2. UV-vis and fluorescence spectra of ManCou1-3 
To gain insight into the ManCou interaction with GLUT5, molecular docking of 
DFT-optimized structures of coumarin conjugates into the exofacial cavity of a 
mammalian fructose transporter GLUT5 (PDB code: 4YB9) using Autodock4 [23] was 
carried out. For each ManCou probe, the resulting complexes were ranked, and the 
complexes were analyzed to identify the position/binding of conformers.  
ManCou1 ManCou2 ManCou3
A B C
 
Figure 2.3. Docking analysis of ManCou1-3. Docking analysis performed with Autodock4. Models 
visualized with PyMol. 
Overall, the analysis of complexes showed the ManCous to bind with the 
uptake relevant residues through the 1-AM moiety but accommodate different 
orientations of the fluorophore (Figure 2.3). All three probes were found to H-bond with 
Tyr32, Gln167, Gln289, and the Glut5-specific Asn294 – residues also found to be 
involved in fructose uptake through GLUT5 [23]. While the binding of 1-AM between 
three complexes involved the same residues, the H-bonding sites at 1-AM were altered 
to accommodate the change in the position of the fluorophore. For ManCou1, the large 
population of conformers was found to orient the coumarin moiety towards His419 and 
Trp420 – residues found to be critical for fructose uptake (Figure 2.3A) [23]. For 
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ManCou3, nine out of ten conformational isomers had the coumarin moiety oriented 
away from these residues into the more open space (Figure 2.3C). Interestingly, for 
ManCou2 (Figure 2.3B), conformations similar to those of ManCou1 and ManCou3 
were detected, suggesting the probe to have duality, as sensed by malignant cells. 
However, a higher level modeling would be required to assess a true binding site(s) 
for these probes and further identifying key interactions contributing to the differences 
in their uptake behavior and cellular impact.  
2.4 Analysis of ManCou1-3 uptake 
The uptake analysis of ManCou1-3 was carried out in breast cancer 
(adenocarcinoma) MCF7 cells. MCF7 cells have been previously studies for GLUT5-
mediated uptake [15, 24-26] thus providing a good platform for initial probe evaluation. 
MCF7 cells were cultured according to standard protocol, seeded in the 96-well plate 
(20000 cells/well) and maintained to adhere for 12 h. Cells were then treated with 
varied concentrations of ManCous 1-3 (in Hank’s solution and media) for 10 min at 37 
°C, and fluorescence was measured after removal of the probe and cell wash. As a 
result, efficient concentration-dependent uptake was observed for all probes with 
ManCou1 having the highest uptake and ManCou3 having the lowest uptake (Figure 
2.4A). The transported probe remains in the cells even after post-incubation in a probe-
free media and repeated washing. This is in agreement with previous observations, 
where 2,5-anhydro-D-mannitol was found to be a suitable substrate for 
phosphofructokinase-1 [27-29]. Accordingly, the lack of back transport is a significant 
point because GLUT transporters, being antiporters,  take up and excrete 
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carbohydrates, but not the phosphorylated products [30]. The comparative analysis of 
non-conjugates coumarins with ManCou (Figure 2.4B) shows that the presence of 1-
AM drastically enhances the uptake, putatively contributing to facilitative internalization 
of probes rather than passive diffusion (as for non-conjugated coumarins).  
A B
 
Figure 2.4. Uptake analysis of ManCou probes in MCF7 cells. A) ManCou probes exhibit concentration-
dependent uptake. B) 1-AM facilitates coumarin uptake (measured for 20 μM ManCou1-3 vs. non-
conjugates coumarins). Data represents the Gained Fluorescence (excitation at 385 nm) measured in a 
96-well plate settings after 10 min incubation of cells with probes in Hank’s buffer. Fluorescence values 
corrected for the quantum yield of ManCou probes. 
24 hours after the uptake no ManCou-induced fluorescence activity was 
observed, suggesting cellular metabolism of the fluorophore. This observation, as well 
as no saturated fluorescence point being found, points toward ManCou sugar base 
undergoing phosphorylation as it enters the cell to and eventually being excreted as a 
metabolite. If the sugar base was not phosphorylated, the probe could easily be 
excreted once the media containing the fluorophore was removed, which was not 
38
 
 
observed even after 30min post incubation. Further testing is needed to determine 
whether the fluorophore itself is metabolized or passively diffuses out of the cell.  
The uptake efficiency of ManCou probes appears to change with the change 
in electronic properties of coumarins. Thus, from three probes, ManCou1 is taken up 
most avidly, ManCou2 is taken up with ~25%, and ManCou3 with 4-fold lesser 
efficiency (Figure 2.4A). The analysis of the uptake kinetics through Michaelis-Menten 
method [18] showed all three probes to have concentration-dependent saturable 
uptake (Figure 2.5), exceeding that of fructose by nearly 1000-fold (15-17 µM for 
ManCou1 and 2, and 35-37 µM for ManCou3). 
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Figure 2.5. Kinetic analysis of ManCou1-3 uptake using Michaelis-Menten Kinetics. Plots depict 
1/fluorescence vs. 1/concentration using data obtained upon treating cells with 1-100 µM ManCou 
concentrations Plots obtained with SigmaPlot13. 
The Z-stack images obtained for MCF7 cells treated with ManCous 1-3 show 
that while ManCou1 and 2 are localized within the membrane and in the cytosol, 
ManCou3 is only present within the cell membrane. The drastic difference in probe 
properties could be rising due to the extended binding of ManCou3 with GLUT5, and 
particularly with Trp419. From all residues identified to bind ManCou3, the Trp419 is a 
key residue located on the transmembrane helix 11 (TM11) of GLUT5 which may inhibit 
the conformation shift between TM10 and TM7 required for the change from the 
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occluded state into the inward open state. In such case, the protein is expected to be 
locked in the outward-open conformation and prevent internalization of the substrate. 
However, it would require a crystal structure with probe bound to confirm this notion.  
ManCou 2ManCou 1 ManCou 3
 
Figure 2.6. Confocal Z-stack images of MCF7 cells treated with 20 uM ManCou1-3 (10 min at 37 °C, 405 
nm excitation, 461 nm (DAPI) emission, 60X objective). 
To assess whether ManCou1-3 exhibit GLUT5 specificity, the impact of 
nutrient carbohydrates, MNBD, GNBD, and cytochalasin B on the probe uptake was 
evaluated. Glucose, fructose, and glucosamine were used as competitive inhibitors of 
ManCou uptake. The impact of glucose and fructose on the uptake was used to 
establish the involvement of glucose transport and fructose transport, respectively, in 
the ManCou uptake. Upon addition of glucose up to concentrations exceeding 
physiological (1-50 mM) no inhibition of ManCou uptake was detected (Figure 2.7A). 
Likewise, no significant change in the uptake efficiency of ManCou probes was 
observed upon crying out uptake analysis in culture media, as opposed to Hank’s 
buffer (Figure 2.7B). These results could rise from the significantly higher affinity of 
ManCou probes to their biological target(s), resulting in a lack of interference of 
nutrients in their uptake. ManCou uptake is however inhibited by MNBD, previously 
shown to target GLUT5, while not impacted by GNBD (targeting glucose transport). 
40
 
 
The observation is suggestive of ManCou probes exhibiting the same mechanism of 
uptake as MNBD, i.e. via GLUT5.  
A B
C D
 
Figure 2.7. Inhibition of ManCou (20 µM) uptake with carbohydrates (A), culture media (B), MNDB (C), 
GNDB (D), and cytochalasin B (E) in MCF7 cells. Data normalized by quantum yield. 
To further assess the role other fructose transporters in ManCou uptake - 
particularly the role of GLUT2 contributing ~12% to total fructose uptake in MCF7 cells 
- cytochalasin B was used a non-competitive inhibitor of glucose uptake through 
GLUTs 1-4. Addition of cytochalasin B in concentrations far exceeding the established 
for GLUTs 1-4 (Ki  = 2-10 µM) did not have impact on the uptake of ManCou probes, 
showing the uptake to be independent of GLUT1-4. The use of glucosamine (up to 50 
mM) as GLUT2-specific substrate also did not induce any effect on ManCou uptake, 
further supporting the lack of GLUT2 participation in the uptake of ManCou probes. 
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Overall, uptake inhibition studies strongly suggest that ManCou probes are 
transported through fructose-specific transporter GLUT5.  
 
Figure 2.8: Uptake of ManCous in MCF7 cells pre-conditioned with or without fructose. Comparative 
analysis of ManCou uptake in fructose-fed (MCF7’), fructose-deprived (MCF7”) and fructose re-fed 
(MCF7*) cells (normalized by MCF7). MCF7, cells grown in standard media; MCF7’, cells fed with 
fructose; MCF7”, cells deprived of fructose; MCF7*, MCF7” cells re-fed with fructose. Data represents the 
Gained Fluorescence. Fluorescence values corrected for the quantum yield of ManCou probes. 
Prolonged exposure of cells to fructose has been shown to primarily increase 
expression of GLUT5 [31]. Hence, preconditioning of MCF7 cells with fructose has 
been carried out to gather further evidence of GLUT5-mediated uptake of ManCou1-
3. To produce fructose-fed cells, MCF7 cells were maintained in the standard growth 
media supplemented with 11mM fructose for ten days. The uptake analysis of 
ManCu1-3 probes in fructose-fed MCF7’ cells showed up to 3-fold increase in uptake 
of ManCou probes (Figure 6A). These results are consistent with previously reported 
MNBD uptake with fructose preconditioned MCF7 cells [16]point towards GLUT5 
driven uptake of ManCou as a result of increased activity of fructose transport or 
metabolism. Starving MCF7 cells of fructose by maintaining them in the dialyzed media 
for ten days decreased ManCou uptake by 2-fold while re-feeding the starved cells by 
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maintaining them in regular media (non-dialyzed) regenerated the levels of the uptake.  
Whether the observed changes result from the alterations in GLUT5 expression or are 
driven by the changes in metabolic activity of preconditioned cells has not yet been 
determined.  
Overall, the inhibition and cell preconditioning studies indicate that Manzcou1-
3 probes are preferentially transported through GLUT5. Within this set of probes, 
ManCou1 behaves as a transport probe, showing clean gradient-driven uptake 
kinetics of first-order in the ManCou. ManCou3 appears to be an effective transport-
labeling probe showing clean receptor-ligand kinetics. ManCou2, overall, shows 
behavior is similar to ManCou1 (i.e. is transported through the membrane). However, 
some interactions with the protein appear to deviate the uptake from pure gradient 
driven first order kinetics.  
 
2.5  ManCous as GLUT5 expression and fructose metabolism probes 
To further determine ManCou’s method of transport, several different human 
cancerous and noncancerous cell lines known to have different expression of GLUT5 
were treated with ManCou 1-3 probes. In normal breast MCF10A cells, known to have 
minimal levels of GLUT5 expression, ManCous have shown significantly lesser uptake 
compared to the cancerous counterparts. This is expected due to documented 
increase in carbohydrate uptake in cancerous cells when compared to their 
noncancerous equivalents. Interestingly H9C2 a cardiac cell line showed minimal to 
no uptake of ManCou1 or 2. However, labeling of the membrane with ManCou3 
showed results similar to that of MCF7 cells. While the expression levels of GLUT5 in 
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H9C2 are not established, it appears that the differences in fluorescence induction by 
ManCou1 vs. Mancou3 may be indicative of a sufficient membrane expression of 
GLUT5 but the lack of metabolizing enzymes to drive gradient-dependent transport of 
ManCou1. This observation provides grounds for further analysis of protein (GLUT5 
vs. metabolizing kinases) expression in cardiac cells. Subsequently, ManCou probes 
could be effectively used to identify GLUT5 expression and fructose metabolism in 
cells.   
 
Figure 2.9. ManCous1 and ManCou3 in the MCF10A model (confocal images): A) cells with no probe; 
B) cells with the probe; C) cells with the probe (fluorescence). MCF10A, non-cancer; MCF10DCIS.com, 
undifferentiated lesions, MCF7, adenocarcinoma; MCF10-neoT, premalignant; and MCF10Ca1a, highly 
malignant. Images taken at 405 nm laser at 461 nm (DAPI) emission (20X objective). 
 
 Considering that there is currently a significant lack in understanding what 
impact fructose uptake inhibition may have on cells, we have evaluated ManCou3 in 
a MCF10 model that systemically demonstrate breast cancer initiation, development, 
and progression [32]. As a result, blocking Glut5 with ManCou3 exerted cytotoxic 
response in malignant cells but not in normal or undifferentiated cells (Figure 2.9).  
MCF10neoTMCF10DCIS.com MCF7MCF10A MCF10Ca1a
A
B
C
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2.6 Conclusions 
 Here three novel carbohydrate-mediated probes have been developed and 
tested, each with their unique kinetics of intercellular uptake. ManCou1 and 2 both 
appear to pass through GLUT5, ManCou3 appears to remain inside the cellular 
membrane. Considering the link between GLUT5 activity and carcinogenesis [33] 
targeting GLUT5 appears to give a new way to achieve cancer-specificity of 
therapeutics or imaging agents. In fact, ManCou probes appears to exhibit desired 
cancer specificity. Moreover, blocking Glut5 with ManCou3 exerted cytotoxic response 
in malignant cells but not in normal or undifferentiated cells. These results may 
potentially lead to a procedure for relatively quick analysis on cancer aggressiveness 
based on fluorescent intensity and accumulation. Also, ManCous provide a proof of 
concept that using carbohydrate mimics, such as 1-AM, may be beneficial for targeted 
drug delivery.  
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Chapter 3 
 
Synthesis of Locked Fructose Analogs 
 
3.1 Introduction 
 
MNBD (1-amino-2,5-deoxy-D-mannitol conjugated to NBD) has been shown to 
preferentially transported through GLUT5 with significantly higher affinity for fructose. 
However, it is unclear what exactly leads to the observed increased affinity. One of the 
possibilities is that GLUT5 may have a preference for the five-member ring 
conformation in addition to hydrophobic interactions induced by the fluorophore. 
Fructose equilibrates between two different ring conformations; furanose (five-
membered ring) and pyranose (six-membered ring) with 25% and 75% populations 
respectfully. GLUT5 affinity towards these ring conformations are unclear due to all 
probes used to determine it exist as anomeric mixtures [1, 2]. To alleviate these 
ambiguous results, probes need to be developed with locked ring conformations to 
understand if GLUT5 is specific for pyranose or furanose forms of the sugar.  
Fructose has four stereocenters. However, the importance of their absolute 
stereochemistry is unclear. Altering these stereocenters may lead to increased 
binding affinity towards the transporter which may lead to potentially potent inhibitors. 
Using organic synthetic techniques to install each stereocenter will allow the 
construction of several unique probes to determine importance of stereochemistry on 
GLUT5 uptake.  This chapter outlines the goals and current progress of probe 
synthesis.  
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3.2 Results and Discussion 
While synthetic development proceeded smoothly for initial reactions in 
relatively high yields, the first significant challenge in the synthesis was the 
apparently simple oxidation of the epoxy system. Common oxidation techniques 
such as PCC and Swern yielded little to no results, however when 1 was subjugated 
to Parikh-Doering conditions the resulting aldehyde was obtained in relatively high 
yield. Wittig olefination proceeded smoothly followed by syn-selective opening using 
Pd tetrakis in the presence of benzyl alcohol. Followed by DIBAL reduction which 
lead to relatively high yield of 83%. After the isolation of 3 the initial goal was to 
oxidize the epoxy alcohol, extend and repeat the Pd-catalyzed opening. However, 
TEMPO oxidation techniques to selectively oxidize the primary alcohol did not 
proceed. Parekh-Doering was then conducted to attempt to get the aldehyde but 
ultimately proved unsuccessful.  
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Scheme 3.1: Overall synthesis of alpha-NBD pyranose probe  
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Moving forward the synthesis will be altered on opening the second epoxide 
using a more traditional anti-opening using a Lewis acid and nucleophile. Following 
reactions are expected to yield similar results to previous attempts before arriving at 
4. Ozonolysis should proceed smoothly to cleave double bond and sequential 
carbonyl reduction using NaBH4 to generate a primary alcohol. Primary alcohol will 
be tosylated using Tosyl chloride (TsCl) before undergoing intercellular cyclization. 
After generation of locked pyranose, the synthetic steps can be easily modified to 
generate altering stereochemistry through Sharpless asymmetric epoxidation to test 
the effect of altering stereocenters.  
This synthesis can be easily altered to generate furanose locked analogs by 
simply stopping after secondary SAE and cyclizing. This will be explored in the future 
as both furanose and pyranose probes are developed to further understand the 
importance of sugar ring size in fructose transport.  
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Scheme 3.2: Synthesis of locked furanose probe 
 
3.3 Conclusions 
Initial groundwork has been developed for a series of probes designed to 
effectively determine stereocenter and ring size importance in fructose transport. 
With synthetic optimizations, these probes should be able to be made on milligram 
scale and carried over for cellular studies.   
3.4 Experimental 
All reactions (unless otherwise stated) were done with flame dried glassware 
and using commercially available reagents without further purification from Sigma-
Aldrich. Silica gel was purchased from Siliflash and has a size of 43-63 µm. Solvents 
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used were taken from dried source. Column chromatography was performed using 
SiliCycle silica gel (230-400 mesh). Thin layer chromatography (TLC) was performed 
using Sigma-Aldrich TLC plates over aluminum support 200um thickness with 25 µm 
particle size. Structural analysis of compounds was carried out with 400 MHz Varian 
NMR instrument. Spectra are reported in parts per million (ppm) relative to the 
solvent resonances (δ), with coupling constants (J) in Hertz (Hz). 
Benzyl Protection of alkyne 
BnBr (1 eq)
rt, H2O, KOH (4eq)
84%
HO
OH
BnO
OH
1  
1,4-butynediol (20 g, 232 mmol, 4 eq) was dissolved in 200 mL of deionized 
water at room temperature and allowed to stir until dissolved. After starting material 
was dissolved potassium hydroxide (13 g, 232 mmol, 4 eq) was added and allowed 
to stand for 30 min. After 30min benzyl bromide was added dropwise and allowed to 
stir overnight. Solution was then extracted with 3 treatments of 75 mL of diethyl ether 
and dried over sodium sulfate. Solvent was removed under reduced pressure to 
leave the yellow crude oil (9.2g) and was then purified over silica gel using ethyl 
acetate/hexane (10/90)solvent system to yield 1 in 84% yield[3]. 1H-NMR CDCl3: δ 
7.2 (m, 5H),  4.80 (s, 2H), 3.80 (d, 2H), 3.90 (d, 2H), 2.8 (s, b, 1H).  
Reduction of alkyne to trans-alkene.  
BnO
OH
BnO OH
Red-Al
0 C to rt, THF  
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Alkyne 1 (9 g, 50.3 mmol) dissolved in 100 mL of dry THF and cooled to 0 Co 
under Ar atmosphere. Red-Al (60% toluene, 30 g, 87 mmol) was then added 
dropwise over a course of 10 min via syringe. Reaction allowed to stand for 1 hour at 
room temperature. Reaction was cooled to 0 Co and 100 mL of 10% sulfuric acid was 
added to quench reaction. The resulting biphasic system was extracted with three 
times with 75 mL of dichloromethane. Solvent was removed under reduced pressure 
to give very light yellow oil (7.8 g) and then purified over silica gel using ethyl 
acetate/hexane (10/90) solvent system to yield 2 in 72% yield [4]. 1H-NMR CDCl3: δ 
7.1 (m, 5H), 5.9 (m, 2H), 4.7 (s, 2H), 4.1 (d, 2H), 4.0 (d, 2H), 2.8 (b, 1H) 
Sharpless asymmetric epoxidation (SAE)  
BnO OH
T-BuOOH (4eq)
-23 C 24h, DCM
BnO OH
O
 
Dried molecular sieves 4Å (4.0 g) were added to dry dichloromethane in a 
flame dried flask at -23 Co before both titanium tetra(isopropoxide) (0.25 eq) and (-) 
diethyl tartrate (0.36 eq) are added to solvent under Ar atmosphere. Dried tert-butyl 
hydroperoxide 3.5M solution in toluene (4eq) was added dropwise over 20min before 
allowing solution to stand with stirring for 30 min. After allotted time allylic alcohol (1 
eq) was dissolved in of dried dichloromethane and added to solution dropwise over 
1hr. Reaction was kept at -20 C° overnight before being warmed to room 
temperature and quenched with 30% NaOH solution in water and stirred for 20 min. 
The molecular sieves were, and salts were then filtered off using vacuum filtration 
before the two phases were separated. Aqueous phase was extracted with three 
washes of 75 mL of dichloromethane. Resulting organic phase was dried over 
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sodium sulfate and concentrated under reduced pressure, followed by purification 
using column chromatograph (silica gel, 10/90 EtOAc-hexane). Resulting in epoxide 
in 78% yield [5]. 1H-NMR CDCl3: δ 7.2 (m, 5H), 4.6 (dd, 2H), 3.9 (m, 1H), 3.7 (dd, 
1H), 3.5 (m, 1H), 3.4 (dd, 1H), 3.2 (m, 1H), 2.9 (b, 1H) 
Parikh-Doering oxidation of 3 
BnO OH
O SO3*py, DMSO
TEA, 0 C to rt, 1h, DCM
BnO O
O
 
To a dried flask dichloromethane (4.3 mL/mmol) and dimethylsulfoxide (0.73 
mL/mmol) were cooled to 0 C° before epoxy alcohol was added to solution with 
stirring under Ar atmosphere. To this solution, TEA (3 eq) was added via syringe, 
and sulfur trioxide pyridine complex (4 eq) purchased from TCI was added rapidly. 
Solution turns from clear to a light brown/red and is allowed to come to room 
temperature. After 2 h, reaction was monitored by TLC before being cooled back 
down to 0 C°. Reaction is quenched by a saturated solution of copper sulfate 
pentahydrate and extracted with dichloromethane. Organic phase was dried over 
sodium sulfate and concentrated under reduced pressure before being purified by 
column chromatography (silica gel, 30/70 EtOAc-hexane). Aldehyde was purified to 
give 53% yield [6]. 1H-NMR CDCl3: δ 10.4 (d, 1H), 7.2 (m, 5H), 4.6 (dd, 2H), 3.9 (m, 
1H), 3.7 (dd, 1H), 3.5 (m, 1H), 3.4 (dd, 1H), 3.2 (m, 1H) 
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3.5 Additional Information 
 
Figure 3.1 H1 NMR at 400Hz for BnO
OH
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 Figure 3.2 C13 NMR at 400Hz for BnO
OH
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Figure 3.3 H1 NMR at 400 Hz for  BnO OH
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Figure 3.4: C13 at 400Hz for  BnO OH
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 Figure 3.5: H1 NMR at 400Hz for BnO
OH
O
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 Figure 3.6 C13 at 400Hz for BnO
OH
O
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 Figure 3.7: H1 at 400Hz for BnO
OO
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 Figure 3.8: C13 at 400Hz for BnO
OO
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Chapter 4 
Future Work 
 
Although current probes have given insight into transporter-substrate tolerance, gaps 
remain. ManCou probe’s C4 position has the ability for many more functional groups to be 
added to give further insight into importance of the electron density of the aromatic system as 
well as how bulky hydrophobic/hydrophilic substitutions may affect uptake. Coumarin 
functionalization can also affect the color of emission and, if used to target different GLUTs, 
may allows for simultaneously tracking of the activity of different GLUTs. 
 
4.1 Finish Synthesis of Furanose/Pyranose Probes 
 With the completion of the ManCou1,2 and 3, strides have been made in 
understanding substrate and payload tolerance. However how exactly GLUT2 or GLUT5 
differentiate between sugar substrates, if they do at all, remains unclear. In Chapter 2 initial 
work has been done in an attempt to construct a multitude of probes in an attempt to 
determine this mechanism. Once probe synthesis is completed using a multitude of cellular 
lines shown to express GLUT5, GLUT2 and neither will need to be exposed to the probes. 
From their fluorescent uptake or lack thereof, should help determine the substrates specific 
toward each transporter.  
4.2 Develop more ManCou Probes 
 Current ManCou probes have given interesting insight on transport and 
transporter/substrate tolerance. However there is significant room for expansion. There are 
several other amino or hydroxyl coumarins commercially available with differing functional 
groups that can give insight in hydrophobic tolerance, sterics, sugar-fluorophore linker role, 
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etc. Manipulating the C4 functional group can also influence the color of the probe as well 
from violet all the way to red. These probes can shed even more light on the confusing topic 
of substrate tolerance. 
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Figure 4.1: Potential future probes 
4.3 Multicolor Assay to Measure GLUT Activity 
 With the construction of ManCou probes and the already tested NBD probes, it is 
now possible to develop a multicolor assay to measure various GLUT activity simultaneously. 
Using multiple colors, it will be possible to track the activity of various transporters in real time 
and potentially diagnose cancer types very quickly and being able to avoid long gene 
sequencing experiments.  
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